Global stock

NYSEUSD

Charles River Laboratories

CRL

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

57/ 100

Overall score·CRL

Current price

357.27USD

26/10/2026

P/E, P/B

Valuation

Neutral

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Forward P/E 23,6 a EV/EBITDA 20,4 ukazují na poměrně náročnější ocenění, zatímco PEG 0,12 je výrazně příznivý, ale může odrážet optimistická očekávání růstu. Slabšími stránkami jsou pokles tržeb, záporná čistá marže a vyšší zadlužení; momentum je naopak silné, protože cena převyšuje 50denní i 200denní průměr.

§ Outlook vs S&P 500Next 12 months

Probably not

Estimated chance of beating the index: about 45%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at Charles River Laboratories (CRL) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

57/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

58/100

Slightly positive signal based on current news, price action and the economy.

56/100

A lower score means the stock is expensive relative to the company's earnings and assets.

149% above fair value

An estimate of what the stock should be worth based on the company's future cash.

-3%

How fast the company's revenue grows year on year.

60/100

How much the company earns from each unit of revenue and from invested capital.

42/100

Debt level, share-price volatility and how resilient the company is in bad times.

65/100

AI estimate of management quality, execution and capital allocation.

78/100

AI estimate of the company's durable competitive advantage.

§ Context and events

Management

Birgit Girshick je CEO a členka představenstva. Strategie společnosti stojí na poskytování laboratorních modelů a externích výzkumných a testovacích služeb pro vývoj léčiv. Michael Gunnar Knell zastává funkci senior viceprezidenta a hlavního účetního, Joseph W. LaPlume vede firemní rozvoj a strategii jako výkonný viceprezident a Victoria L. Creamer je výkonnou viceprezidentkou a ředitelkou pro lidské zdroje.

Articles about Charles River Laboratories, in Czech (0)

No articles yet. New analyses are published daily.

§ Upcoming results

4 November 2026

in 8 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is Charles River Laboratories (CRL)?

Charles River Laboratories (CRL) is a global stock traded on NYSE. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Charles River Laboratories price today?

As of 26 October 2026, Charles River Laboratories trades at about 357.27 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Charles River Laboratories?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Charles River Laboratories pay a dividend?

Charles River Laboratories either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Charles River Laboratories a good investment in 2026?

Our AI signal currently rates Charles River Laboratories as slightly positive (score 58/100). Financial health comes out at 57/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 149 % above its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy Charles River Laboratories

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly positive

Earnings in 8 days

On 4 November 2026 the company publishes its quarterly results. This period tends to bring large price moves.

News summary

Fresh news

Signal 27/10, 05:02

Podání SEC uvádí prodej akcií Charles River za 8,4 mil. USD; před výsledky za 3. čtvrtletí jde o opatrný signál, jeho váhu může změnit výhled firmy.

Růst ceny o 19 % za týden a 22 % za měsíc spolu s rostoucím trendem podporuje krátkodobé momentum. RSI 78 a volatilita 100 ale zvyšují riziko korekce; střednědobý výhled zůstává smíšený.

Risks: Pokračující vysoká volatilita, pokles pod nedávný trend nebo slabší firemní výhled by současný pozitivní obraz oslabily.

More about the signal

Risks: Pokračující vysoká volatilita, pokles pod nedávný trend nebo slabší firemní výhled by současný pozitivní obraz oslabily.

Signal history· 2

24/1021:0170 · Slightly positive
Charles River, Labcorp a FDA 22. října 2026 oznámily spolupráci na metodách hodnocení rizika zneužití léčiv; dopad podpoří širší využití těchto metod v regulaci a vývoji.
23/1000:0271 · Strongly positive
Charles River uzavřel s FDA a Labcorp dohodu o vývoji metod pro hodnocení potenciálu zneužití léčiv; přínos by potvrdilo širší využití těchto služeb.

The full 90-day signal history is part of Premium.

Ask the AI

§ Model fair value (DCF)

Overvalued149% above fair value

143.76

range 117.5 – 179.0

Current price

357.27 USD

26 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

143.76 USD

range 117.5 USD – 179.0 USD

: 4.0%
: 10.5%
: 10.53 USD

Růst 4 % p.a. je konzervativní vzhledem k poklesu tržeb a zápornému EPS, přestože dodaný FCF je kladný. Diskontní sazba 10,5 % zohledňuje nadprůměrnou betu a vyšší zadlužení; terminální růst 2,5 % odpovídá dlouhodobému růstu ekonomiky.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 16 of 18

Valuation score

1/ 6

5/6 tests available

1. Below DCF fair value

148.5% above the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

100% above the 1-year low (149.9 USD to 357.3 USD), based on stored daily prices.

4. P/E vs. similar companies

The sector sample has only 72 companies; scoring needs at least 8.

5. P/E relative to growth

PEG 0.1; a lower value means cheaper growth.

6. Analyst price target

-12.3% vs. the current price, 15 analysts.

Price vs DCF

Current price

357.3 USD

Low 117.5 USDHigh 179.0 USD

Current priceDCF midpoint: 143.8 USD

Price vs analyst target

Current price

357.3 USD

Low 145.0 USDHigh 357.0 USD

Current priceAverage: 313.2 USD

DCF gap

above range

148.5% above the DCF midpoint (143.8 USD).

Analyst target

-12.3%

Average target 313.2 USD vs. price 357.3 USD.

Analyst consensus

Target range

145.0 USD - 357.0 USD

Coverage

15 analysts

Analyst consensus

1.7 / 5

Changes 180 d

+3 / -1

EPS next year

12.3%

Revenue next year

2.6%

Valuation multiples

23.6

5.1

3.6

20.4

0.1

52-week range100% above the low

149.9 USD357.3 USD

-3.0%

-6.0%

-7.5%

Price vs 50D25.6%

Price vs 200D67.6%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 26/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

good

Vedení rozšiřuje kapacity akvizicemi a posilováním působnosti v Asii, což podporuje strategickou exekuci. Skóre snižují zvýšená rizika v oblasti práv akcionářů a odměňování.

strong

Charles River těží z rozsahu, odborných znalostí a zavedených vztahů s farmaceutickými a biotechnologickými klienty v oblasti výzkumu a předklinického testování. Regulační know-how a specializované kapacity vytvářejí překážky vstupu, i když poptávka zůstává citlivá na investice klientů.

Information

Type: Global stock
Symbol: CRL
Exchange: NYSE
Currency: USD
Sector: Healthcare
: 14.4B USD
: 105.1 %
: 1.40

§ Risk profile

Výsledky mohou oslabit škrty ve výzkumných rozpočtech farmaceutických a biotechnologických firem, nižší poptávka po předklinických službách nebo ztráta významných zákazníků. Českému investorovi navíc může dolarová expozice snížit korunový výnos.

Ask the AI about Charles River Laboratories All signals